Search results
Showing 511 to 525 of 1254 results for criteria
Partial replacement of the meniscus of the knee using a biodegradable scaffold (HTG289)
Evidence-based recommendations on partial replacement of the meniscus of the knee using a biodegradable scaffold. This involves placing a biodegradable implant into the meniscus to support regrowth and repair of the damage.
View recommendations for HTG289Show all sections
Sections for HTG289
LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands (MIB29)
NICE has developed a medtech innovation briefing (MIB) on LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
This guideline covers identifying, assessing and managing alcohol-use disorders (harmful drinking and alcohol dependence) in adults and young people aged 10 to 17 years. It aims to reduce harms (such as liver disease, heart problems, depression and anxiety) from alcohol by improving assessment and setting goals for reducing alcohol consumption.
Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)
Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease in adults.
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)
Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.
This guideline covers investigating all suspected thyroid disease and managing primary thyroid disease (related to the thyroid rather than the pituitary gland). It does not cover managing thyroid cancer or thyroid disease in pregnancy. It aims to improve quality of life by making recommendations on diagnosis, treatment, long-term care and support.
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.
Before 2022, we used different processes for assessing technologies. You can view the previous process and methods guides below.
Evidence-based recommendations on vinflunine (Javlor) for treating advanced transitional cell carcinoma of the urothelial tract in adults.
NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds
Evidence-based recommendations on nivolumab (Opdivo) for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.
Evidence-based recommendations on erlotinib (Tarceva) for treating EGFR-TK-positive non-small-cell lung cancer in adults.
Evidence-based recommendations on amivantamab (Rybrevant) with carboplatin and pemetrexed for untreated advanced non-small-cell lung cancer with activating EGFR exon 20 insertion mutations in adults.